



Available online at www.sciencedirect.com

ScienceDirect

journal homepage: www.e-jmii.com



Corrigendum to < ‘Efficacy and safety of anti-interleukin-5 therapy in patients with chronic obstructive pulmonary disease: A meta-analysis of randomized, controlled trials’ > [J Microbiol Immunol Infect 55 (1) (2022) 26–35]



Shao-Huan Lan ^{a,1}, Chih-Cheng Lai ^{b,1}, Shen-Peng Chang ^c,
Chun-Chun Hsu ^{d,e,f}, Cheng-Hsin Chen ^g, Ya-Hui Wang ^h,
Yueh Lan Huang ^{g,**}, Cheng-Yi Wang ^{g,*}, You-Shuei Lin ^{i,***}

^a School of Management, Putian University, PR China

^b Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan Branch, Tainan, Taiwan

^c Yijia Pharmacy, Tainan, Taiwan

^d School of Respiratory Therapy, College of Medicine, Taipei Medical University, Taipei, Taiwan

^e Division of Pulmonary Medicine, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan

^f Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan

^g Department of Internal Medicine, Cardinal Tien Hospital and School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan

^h Medical Research Center, Cardinal Tien Hospital and School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan

ⁱ Department of Physiology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan

DOI of original article: <https://doi.org/10.1016/j.jmii.2020.11.001>.

** Corresponding author.

* Corresponding author.

*** Corresponding author.


E-mail addresses: lionet0729@gmail.com (Y.L. Huang), cywang@mospital.com (C.-Y. Wang), yslin@tmu.edu.tw (Y.-S. Lin).

¹ The two authors contributed equally.

<https://doi.org/10.1016/j.jmii.2023.10.003>

1684-1182/Copyright © 2023, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.

Fig. 3



Corrected version	
Page 3 Results The risk of COPD exacerbation Page 4	<p>While we analyzed the effect of each anti-IL-5 agent, only benralizumab was associated with a lower risk of COPD exacerbation</p> <p>Although mepolizumab was found to be associated with a lower risk of COPD exacerbation when compared with the placebo, the difference was not statistically significant (rate ratio, 0.90; 95% CI, 0.77–1.06, I² = 62%).</p>

The authors would like to apologise for any inconvenience caused.